The therapeutic potential of cerebrolysin in the preventive therapy of Alzheimer's disease

Zhurnal Nevrologii i Psihiatrii imeni S.S. Korsakova

Volumn 108, Issue 8, 2008, Pages 24-28

  Gavrllova, S I ^a   Fyodorov, Ya B ^a   Kolykhalov, I V ^a   Odinak, M M ^a   Emelin, A Yu ^a   Kashin, A V ^a   Seleznyova, N D ^a   Kalyn, Ya B ^a   Roshchina, I F ^a  

^a NONE

Author keywords

Alzheimer's disease; Cerebrolysin; Mild cognitive impairment

Indexed keywords

EID: 52049121286     PISSN: 19977298     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (28)

1. Russian source
2. Russian source
3. Russian source
4. Russian source
5. Russian source
6. Russian source
7. Russian source
8. Russian source
9. Russian source
10. Russian source
11. Alvarez X.A., Lombardi V.R., Fernandez-Novoa L. et al. Cerebrolysin reduces microglial activation in-vivo and in-vitro: a potencial mechanism of neuroprotection. J Neural Transm 2000; 59: Suppl 281-292.
12. Axai F., Hiruma S., Sato T. et al. Neurotrphic faktor-like effect of FPF 1070 on ceptal cholinergik neurons after, transections of fimbria - fornix in the rat brain. Histol Hystopatol 1992; 7: 213-221.
13. Gonzales M.E., Francis L., Castellano O. Antioxidant systemic effect of short - term Cerebrolysin administration. J Neural Transm 1998; 53: Suppl 255-275.
14. Hachinski V.C., Lassen N.A., Marshall J. Multi-infarct dementia: a cause of mental deterioration in the elderly. Lancet 1974; 2: 207-210.
15. Hachinski V.C. The decline and resurgence of vascular dementia. Can Med Assoc J 1990; 142: 107-111.
16. Hefti F. Growth factors and neurodegeneration. In: Neurodegenerative Disease. Ed. by D. Calne. Philadelphia: W.W. Saunders 1994; 177-194.
17. Hutter-Paier B., Steiner E., Windisch M. Cerebrolisin protects isolated cortical neurons from neurodegeneration ufter brief histotoxic hypoxia. Neural Transm Suppl 1998; 53: 351-361.
18. Masliah E., Armasolo F., Veinbergs I. et al. Cerebrolisin ameliorates performance deficits, and neuronal damage in apolipoprotein E-deficient mice. Pharmacol Biochem Behav 1999; 62: 2: 239-245.
19. Morris J.C. The Clinical Dementia Rating (CDR): current version and scoring rules. Neurology 1993; 43: 2412-2414.
20. Russian source
21. Petersen R.C., Touchon J. Consensus on mild cognitive impairment. Research and Practice in Alzheimer's Disease, E.A.D.C./A.D.C.S. Joint Meeting, Serdi Publisher. Paris 2005; 10: 24-32.
22. Reiner M., Brunnbayer M., Dunky A. et al. Therapeutic results with Cerebrolysin in the treatment of dementia. Wien Mod Wochenschr 1997; 147: 426-431.
23. Reinprecht I., Gschanes A., Windisch M., Fachbach G. Two peptidergic drugs increase the synaptophysin immunoreactivity in brains of 24-month-old-rats. Histochem J 1994; 31: 395-401.
24. Reisberg B., Ferris S.H., de Leon M.J. et al. The global deterioration scale (GDS). An instrument for the assessment of primary degenerative dementia. Am J Psychiat 1982; 139: 1136-1139.
25. Rockenstein E., Mallory M., Mante M. et al. Effects of Cerebrolysin in Human APP Transgenic Animal Models of Alzheimer's Disease. Neurobiol Aging 2000; 21: 168.
26. Ruther E., Ritter R., Apecechea M. et al. Efficacy of the Peptidergic Nootropic Drug Cerebrolysin in Patients with senile dementia of the Alzheimer Type. Pharmacopsychiatry 1994; 27: 1: 32-40.
27. Valouskova V., Francis-Turner L. Can Cerebrolysin influence chronic deterioration of spatial learning and memory? J Neural Transm 1998; 52: Suppl: 343-349.
28. Windisch M., Gschanes A., Hutter-Paier B. Neurotrophic activities and therapeutic experience with a brain derived peptide preparation. J Neural Transm 1998; 53 Suppl: 289-298.